TY - JOUR
T1 - Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies
AU - Kulkarni, Sanjay
AU - Pandey, Abhijeet
AU - Mutalik, Srinivas
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Here, we focus on nanoparticle (NP)-based platforms for the targeted therapy of haematological malignancies (HMs), providing an overview of surface-modified nanoplatforms, such as aptamer-, metal-, nucleic acid-, toxin, and peptide-modified NPs, for the efficient targeting of tumor cells. We discuss NPs targeting subcellular compartments, including mitochondria, nucleus and Golgi apparatus, for enhanced therapy of HMs. We also review stimuli-responsive nanoplatforms for modulating site-specific release of drugs. We provide insight into alternative modes of therapy, such as phototherapy, gene therapy, dendritic cell (DC) therapy, and radiotherapy, highlighting recent advances in the treatment of HMs.
AB - Here, we focus on nanoparticle (NP)-based platforms for the targeted therapy of haematological malignancies (HMs), providing an overview of surface-modified nanoplatforms, such as aptamer-, metal-, nucleic acid-, toxin, and peptide-modified NPs, for the efficient targeting of tumor cells. We discuss NPs targeting subcellular compartments, including mitochondria, nucleus and Golgi apparatus, for enhanced therapy of HMs. We also review stimuli-responsive nanoplatforms for modulating site-specific release of drugs. We provide insight into alternative modes of therapy, such as phototherapy, gene therapy, dendritic cell (DC) therapy, and radiotherapy, highlighting recent advances in the treatment of HMs.
UR - http://www.scopus.com/inward/record.url?scp=85073717347&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073717347&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2019.10.001
DO - 10.1016/j.drudis.2019.10.001
M3 - Review article
C2 - 31614201
AN - SCOPUS:85073717347
SN - 1359-6446
JO - Drug Discovery Today
JF - Drug Discovery Today
ER -